| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | pitstop2 | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | Nutlin-3 | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | 0.0022 | 0.9 |